Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASH Data On CRS Helps Determine Where Anti-CD20 Bispecifics Fit Versus CAR-T

Executive Summary

From the CD20-directed bispecific antibody studies presented at ASH, the risk and severity of cytokine release syndrome is being viewed as a way to determine whether the bispecifics will be used before, after or instead of CAR-Ts.

You may also be interested in...



Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space

The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.

Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse

MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.

Biogen’s Opt-In On Roche’s CD20 Drugs Is Gift That Keeps On Giving

Roche has enjoyed decades-long success with its string of CD20-targeting drugs – and thanks to a legacy opt-in, so has Biogen.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel